ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 140 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $293,679 | -26.1% | 14,640 | +4.0% | 0.00% | – |
| Q2 2023 | $397,225 | +71.3% | 14,081 | +4.5% | 0.00% | – |
| Q1 2023 | $231,821 | -20.1% | 13,478 | -6.4% | 0.00% | – |
| Q4 2022 | $290,016 | +12.8% | 14,400 | +21.1% | 0.00% | – |
| Q3 2022 | $257,000 | -16.0% | 11,891 | +9.3% | 0.00% | – |
| Q2 2022 | $306,000 | -44.1% | 10,880 | -8.3% | 0.00% | – |
| Q1 2022 | $547,000 | -43.7% | 11,862 | +2.6% | 0.00% | -100.0% |
| Q4 2021 | $972,000 | -7.9% | 11,559 | -27.0% | 0.00% | 0.0% |
| Q3 2021 | $1,055,000 | +34.9% | 15,831 | +7.8% | 0.00% | 0.0% |
| Q2 2021 | $782,000 | +205.5% | 14,691 | +148.5% | 0.00% | – |
| Q1 2021 | $256,000 | -28.9% | 5,911 | -14.7% | 0.00% | – |
| Q4 2020 | $360,000 | – | 6,932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |